MetaCap

Attovia Therapeutics (ATTO) vs Surrozen (SRZN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Attovia Therapeutics is the larger company by market cap ($690.3 million vs $596.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATTO-31.05%SRZN+29.66%
+58%+8%-42%
Aug 5, 20261 yearNov 20, 2026
ATTO-25.14%SRZN+11.09%
+30%-4%-39%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATTO versus SRZN key metrics
MetricATTOSRZN
Share price$15.10$28.46
Market cap$690.26M$596.40M
1-day change-3.08%-7.21%
YTD return—+25.93%
1-year return—+115.61%
5-year return—-78.97%
EPS (TTM)$-5.53$-41.94
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.48M
Revenue growth (YoY)—-67.37%
Net income (latest FY)—$-242.03M
Operating margin—-1210.58%
Net margin—-6960.77%
52-week high$28.00$37.83
52-week low$12.94$12.79
Distance from 52-week high-46.07%-24.77%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+186.09%+123.12%
Average volume337.27K537.16K
Shares outstanding45.71M20.96M
Employees5044
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Attovia Therapeutics

ATTO stock →

Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 50 employees

About Surrozen

SRZN stock →

Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees

ATTO vs SRZN FAQ

Which is bigger, Attovia Therapeutics or Surrozen?

Attovia Therapeutics (ATTO) is larger, with a market capitalization of $690.26M compared with $596.40M for Surrozen (SRZN).

Are Attovia Therapeutics and Surrozen in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons